Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • M&A / Deals
  • Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant
  • M&A / Deals

Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant

Pharmaceutical Technology

Vivani's NanoPortal technology delivers medication steadily over long periods of time.

Metabolic & GLP-1

Read full story

pharminent July 8, 2026 (Last updated: July 15, 2026)

Pharmaceutical Technology

Vivani’s NanoPortal technology delivers medication steadily over long periods of time.

Metabolic & GLP-1

Read full story

Post navigation

Previous: Novartis Pays $1.1B Upfront for Myricx Bio ADC Platform
Next: AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical

Related Stories

  • M&A / Deals

Solstice Oncology secures $225m to drive porustobart’s development for cancer

pharminent September 10, 2026
  • M&A / Deals

UK’s Claret Capital raises 575m for European biotechs

pharminent September 7, 2026
  • M&A / Deals

GSK wagers up to $1.3B on a different kind of cancer drug

pharminent September 3, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.